HER2 testing for samples from recurrent or metastatic disease is recommended by the 2013 update of the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline [1], due to the possibility that HER2 status may differ in recurrent disease. The gene discussed is ERBB2; the disease is metastatic neoplasm.